KPI data tables
Sanofi operating metrics behind the KPI charts, newest period first (up to 24 periods per chart). Periods use each company's own fiscal labels where the source does; each table names its source.
| Period | Beyfortus sales |
|---|---|
| Q3 2026 | 631 |
| Q2 2026 | 108 |
| Q1 2026 | 284 |
| Q4 2025 | 686 |
| Q3 2025 | 739 |
| Q2 2025 | 72 |
| Q1 2025 | 284 |
| Q4 2024 | 841 |
| Q3 2024 | 645 |
| Q2 2024 | 18 |
| Q1 2024 | 182 |
| Q4 2023 | 410 |
| Q3 2023 | 137 |
Source: Sanofi Form 6-K Exhibit 99.1 earnings releases, Beyfortus (RSV) row in the Vaccines net sales table and Appendix 1 (amounts in € million, quarterly flow not H1/9M/FY). Later filing wins. Q3 2026 €631 million https://www.sec.gov/Archives/edgar/data/1121404/000112140426000009/pressreleaseq32026english.htm Q2 2026 €108 million https://www.sec.gov/Archives/edgar/data/1121404/000112140426000008/pressreleaseq22026english.htm Q1 2026 €284 million https://www.sec.gov/Archives/edgar/data/1121404/000112140426000004/pressreleaseq12026english.htm Q4 2025 €686 million https://www.sec.gov/Archives/edgar/data/1121404/000112140426000001/pressreleaseq42025english.htm Q3 2025 €739 million https://www.sec.gov/Archives/edgar/data/1121404/000112140425000026/pressreleaseq32025english.htm Q2 2025 €72 million https://www.sec.gov/Archives/edgar/data/1121404/000112140425000020/pressreleaseq22025english.htm Q1 2025 €284 million https://www.sec.gov/Archives/edgar/data/1121404/000112140425000013/pressreleaseq12025english.htm Q4 2024 €841 million https://www.sec.gov/Archives/edgar/data/1121404/000112140425000002/pressreleaseq42024english.htm Q3 2024 €645 million https://www.sec.gov/Archives/edgar/data/1121404/000112140424000020/pressreleaseq32024english.htm Q2 2024 €18 million https://www.sec.gov/Archives/edgar/data/1121404/000112140424000018/pressreleaseq22024english.htm Q1 2024 €182 million https://www.sec.gov/Archives/edgar/data/1121404/000112140424000011/pressreleaseq12024english.htm Q4 2023 €410 million https://www.sec.gov/Archives/edgar/data/1121404/000112140424000003/pressreleaseq42023english.htm Q3 2023 €137 million https://www.sec.gov/Archives/edgar/data/1121404/000112140423000026/pressreleaseq32023english.htm
| Period | United States | Europe | Rest of World |
|---|---|---|---|
| Q3 2026 | 4,376 | 588 | 723 |
| Q2 2026 | 3,899 | 583 | 672 |
| Q1 2026 | 3,023 | 563 | 584 |
| Q4 2025 | 3,182 | 509 | 555 |
| Q3 2025 | 3,073 | 504 | 579 |
| Q2 2025 | 2,807 | 485 | 540 |
| Q1 2025 | 2,476 | 459 | 545 |
Source: Sanofi Form 6-K Exhibit 99.1 earnings releases, Dupixent row in net sales by medicine and geography (amounts in € million). Q3 2026 (30 Oct 2026) https://www.sec.gov/Archives/edgar/data/1121404/000112140426000009/pressreleaseq32026english.htm Q2 2026 (30 Jul 2026) https://www.sec.gov/Archives/edgar/data/1121404/000112140426000008/pressreleaseq22026english.htm Q1 2026 https://www.sec.gov/Archives/edgar/data/1121404/000112140426000004/pressreleaseq12026english.htm Q4 2025 / FY 2025 https://www.sec.gov/Archives/edgar/data/1121404/000112140426000001/pressreleaseq42025english.htm Q3 2025 https://www.sec.gov/Archives/edgar/data/1121404/000112140425000026/pressreleaseq32025english.htm Q2 2025 https://www.sec.gov/Archives/edgar/data/1121404/000112140425000020/pressreleaseq22025english.htm Q1 2025 https://www.sec.gov/Archives/edgar/data/1121404/000112140425000013/pressreleaseq12025english.htm
| Period | United States | Europe | Rest of World |
|---|---|---|---|
| Q3 2026 | 8,603 | 2,579 | 3,262 |
| Q2 2026 | 6,344 | 2,141 | 3,112 |
| Q1 2026 | 5,289 | 2,163 | 3,057 |
| Q4 2025 | 5,803 | 2,436 | 3,064 |
| Q3 2025 | 6,838 | 2,589 | 3,007 |
| Q2 2025 | 4,878 | 2,101 | 3,015 |
| Q1 2025 | 4,657 | 2,043 | 3,195 |
Source: Sanofi Form 6-K Exhibit 99.1 earnings releases, Sales by geography table (amounts in € million). Q3 2026 https://www.sec.gov/Archives/edgar/data/1121404/000112140426000009/pressreleaseq32026english.htm US 8,603 / Europe 2,579 / Rest of World 3,262. Q2 2026 https://www.sec.gov/Archives/edgar/data/1121404/000112140426000008/pressreleaseq22026english.htm US 6,344 / Europe 2,141 / Rest of World 3,112. Q1 2026 https://www.sec.gov/Archives/edgar/data/1121404/000112140426000004/pressreleaseq12026english.htm 5,289 / 2,163 / 3,057. Q4 2025 https://www.sec.gov/Archives/edgar/data/1121404/000112140426000001/pressreleaseq42025english.htm 5,803 / 2,436 / 3,064. Q3 2025 https://www.sec.gov/Archives/edgar/data/1121404/000112140425000026/pressreleaseq32025english.htm 6,838 / 2,589 / 3,007. Q2 2025 https://www.sec.gov/Archives/edgar/data/1121404/000112140425000020/pressreleaseq22025english.htm 4,878 / 2,101 / 3,015. Q1 2025 https://www.sec.gov/Archives/edgar/data/1121404/000112140425000013/pressreleaseq12025english.htm 4,657 / 2,043 / 3,195.
| Period | Pharma launches |
|---|---|
| Q3 2026 | 1,390 |
| Q2 2026 | 1,305 |
| Q1 2026 | 1,171 |
| Q4 2025 | 1,121 |
| Q3 2025 | 1,046 |
| Q2 2025 | 897 |
| Q1 2025 | 847 |
| Q4 2024 | 827 |
| Q3 2024 | 727 |
| Q2 2024 | 689 |
| Q1 2024 | 606 |
Source: Sanofi Form 6-K Exhibit 99.1 earnings releases, Pharma launches (*) row in Appendix 1 net sales by medicine/vaccine (amounts in € million, quarterly flow not H1/9M/FY). Not the combined Launches (*, **) row. Later filing wins. Q3 2026 €1390 million https://www.sec.gov/Archives/edgar/data/1121404/000112140426000009/pressreleaseq32026english.htm Q2 2026 €1305 million https://www.sec.gov/Archives/edgar/data/1121404/000112140426000008/pressreleaseq22026english.htm Q1 2026 €1171 million https://www.sec.gov/Archives/edgar/data/1121404/000112140426000004/pressreleaseq12026english.htm Q4 2025 €1121 million https://www.sec.gov/Archives/edgar/data/1121404/000112140426000001/pressreleaseq42025english.htm Q3 2025 €1046 million https://www.sec.gov/Archives/edgar/data/1121404/000112140425000026/pressreleaseq32025english.htm Q2 2025 €897 million https://www.sec.gov/Archives/edgar/data/1121404/000112140425000020/pressreleaseq22025english.htm Q1 2025 €847 million https://www.sec.gov/Archives/edgar/data/1121404/000112140425000013/pressreleaseq12025english.htm Q4 2024 €827 million https://www.sec.gov/Archives/edgar/data/1121404/000112140425000002/pressreleaseq42024english.htm Q3 2024 €727 million https://www.sec.gov/Archives/edgar/data/1121404/000112140424000020/pressreleaseq32024english.htm Q2 2024 €689 million https://www.sec.gov/Archives/edgar/data/1121404/000112140424000018/pressreleaseq22024english.htm Q1 2024 €606 million https://www.sec.gov/Archives/edgar/data/1121404/000112140424000011/pressreleaseq12024english.htm
| Period | Polio/pertussis/Hib (incl. Heplisav-B from Q1 2026) | Meningitis, travel, and endemic | Beyfortus | Influenza, COVID-19 |
|---|---|---|---|---|
| Q3 2026 | 823 | 476 | 631 | 1,256 |
| Q2 2026 | 700 | 287 | 108 | 54 |
| Q1 2026 | 664 | 278 | 284 | 67 |
| Q4 2025 | 551 | 227 | 686 | 575 |
| Q3 2025 | 642 | 451 | 739 | 1,525 |
| Q2 2025 | 693 | 307 | 72 | 141 |
| Q1 2025 | 668 | 302 | 284 | 73 |
Source: Sanofi Form 6-K Exhibit 99.1 earnings releases, Vaccines net sales table (amounts in € million). Q3 2026 https://www.sec.gov/Archives/edgar/data/1121404/000112140426000009/pressreleaseq32026english.htm PPH 823 / meningitis, travel and endemic 476 / Beyfortus 631 / influenza, COVID-19 1256. Q2 2026 https://www.sec.gov/Archives/edgar/data/1121404/000112140426000008/pressreleaseq22026english.htm PPH 700 / meningitis, travel and endemic 287 / Beyfortus 108 / influenza, COVID-19 54. Q1 2026 https://www.sec.gov/Archives/edgar/data/1121404/000112140426000004/pressreleaseq12026english.htm 664 / 278 / 284 / 67. Q4 2025 https://www.sec.gov/Archives/edgar/data/1121404/000112140426000001/pressreleaseq42025english.htm 551 / 227 / 686 / 575. Q3 2025 https://www.sec.gov/Archives/edgar/data/1121404/000112140425000026/pressreleaseq32025english.htm 642 / 451 / 739 / 1525. Q2 2025 https://www.sec.gov/Archives/edgar/data/1121404/000112140425000020/pressreleaseq22025english.htm 693 / 307 / 72 / 141. Q1 2025 https://www.sec.gov/Archives/edgar/data/1121404/000112140425000013/pressreleaseq12025english.htm 668 / 302 / 284 / 73.